Evaluation of Camizestrant Pharmacokinetics, Safety, and Tolerability in Post-Menopausal Females with Moderate or Severe Hepatic Impairment

The primary objective of this study is to evaluate the effect of **hepatic impairment** on the pharmacokinetics, safety, and tolerability of Camizestrant in post-menopausal female subjects. Understanding the pharmacokinetic profile in individuals with moderate or severe hepatic impairment is clinically relevant as it informs dosing adjustments and safety considerations for this population. The study aims to ensure that Camizestrant can be used safely and effectively in patients with compromised liver function, which is crucial for optimizing therapeutic outcomes and minimizing adverse effects.

The clinical trial involves a total of **14 participants** who are exclusively female, with an age range corresponding to categories 3 and 4, which typically includes adults and older adults. The study population is characterized by individuals with **moderate or severe hepatic impairment**. Participants were selected based on specific criteria, although the principal inclusion criteria were not provided by the sponsor. The trial does not include a vulnerable population. Lifestyle considerations such as diet, physical activity, or habits were not specified in the available data. The selection process and any additional demographic details were not disclosed by the sponsor.

The clinical trial is designed to evaluate the effect of hepatic impairment on the pharmacokinetics, safety, and tolerability of **Camizestrant** in post-menopausal female subjects. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is May 1, 2023, with an anticipated end date of February 22, 2024. The trial will involve participants with moderate or severe hepatic impairment.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into the study. The trial will include multiple follow-up visits to monitor the pharmacokinetics, safety, and tolerability of the investigational product. These visits will be scheduled at regular intervals throughout the study duration. The end-of-study visit will occur after the final follow-up, where comprehensive assessments will be conducted to gather final data.

The expected length of participant involvement will span from the initial screening visit through to the end-of-study visit, aligning with the overall trial duration. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any other protocol-defined criteria that compromise participant safety or data integrity. The trial is structured to ensure rigorous monitoring and adherence to ethical standards throughout its course.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. The absence of these details precludes a comprehensive description of the treatment regimen, dosing schedules, or participant compliance monitoring. Consequently, no further relevant information about drug administration can be provided based on the available data.

The clinical trial is in Phase 3 and is scheduled to have an estimated recruitment start date of May 1, 2023, with an estimated end date of February 22, 2024. The efficacy of the investigational treatment will be assessed through a structured evaluation process. Although specific primary and secondary endpoints are not detailed, typical Phase 3 trials often involve the use of validated scales, laboratory tests, and patient-reported outcomes to measure efficacy. These assessments are usually conducted at predetermined timepoints throughout the trial, such as baseline, mid-treatment, and end-of-treatment, to monitor changes in clinical parameters. The data collected will be analyzed to determine the treatment's impact on the disease, with the goal of establishing its efficacy in comparison to standard treatments or placebo. The trial's design and methodology will adhere to rigorous scientific standards to ensure the reliability and validity of the results.